Founded in 2017, Vyome Therapeutics operates in Health Tech industry. Originally focused on addressing unmet needs in the dermatology space with innovative solutions, Vyome has since broadened its app...
Funding stage:
Venture Round
Last funding:
31/12/2021
Total funding:
$48.30 Mn+
Revenue:
Investors
Employee count:
19
Last 90d
19
Last 90d
Web traffic:
2.04K
2.04K
Last 30d
Last 30d
Glassdoor Rating:
Vyome Therapeutics: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders14
Latest Filing Date30 March 2024- Funding Events35
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Vyome Therapeutics
As of 31 March 2024, Vyome Therapeutics's equity is held by 11 shareholders, with the top three being Kalaari Capital Partners II LLC, Perceptive Life Sciences Master Fund Ltd, and Romulus Vyome Special Opportunity III LLC.
Kalaari Capital Partners II LLC holds the largest stake in Vyome Therapeutics at 22.0% as of 31 March 2024.
As of 31 March 2024, founders collectively hold 5.6% equity in Vyome Therapeutics.
As of 31 March 2024, investors collectively hold 88.4% equity in Vyome Therapeutics.
Vyome Therapeutics's ESOP pool stands at 6.0% of total equity as of 31 March 2024.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links